Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 524 (LINC00524) is a long non-coding RNA, meaning it does not encode a protein product but instead functions at the RNA level. It is overexpressed in multiple cancers, particularly breast cancer, where it promotes cell proliferation, migration, invasion, and metastasis. Mechanistically, it interacts with proteins such as TDP43 to stabilize their expression, which in turn promotes tumor progression. High levels of LINC00524 expression have been associated with poor prognosis in breast cancer. As a molecular entity, LINC00524 belongs to the family of long non-coding RNAs and is being investigated in preclinical settings as a potential biomarker and possible target for RNA-based therapeutic approaches, though no drugs currently target it directly[1][5].
no approved or experimental mechanism for drugs specifically targeting LINC00524; its function is mainly as a molecular scaffold or regulator via RNA-protein interactions, such as binding TDP43 in cancer
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 524 (LINC00524).